Treating opioid use disorders in your own general practice
From July 2023 Opioid Agonist Treatments [OAT] including methadone and buprenorphine products have been added to the Highly Specialised Drugs (HSDs) program which means they are subsidised through the Pharmaceutical Benefits Scheme (PBS) and administered under Section 100.
The inclusion of OAT medicines is intended to address the core issues of patient affordability and equitable access to OAT medicines through the PBS, such that access to PBS subsidised OAT medicines aligns with usual PBS arrangements including the PBS co-payment and safety net arrangements.
Patients will no longer be charged private daily dispensing or dosing fees by PBS approved pharmacies to access their medicines and these changes have the potential to significantly impact many of the private OAT clinics currently in operation.
If you would like to understand how these changes affect you or are interested in treating opioid use disorders in your own General Practice, the GP Liaison Service for Alcohol and other Drugs [GLAD] can assist you with starting people on OAT as well as providing clinical advice about withdrawal management, tapering programs and any other complex care issues.
Education for GPs- Opioid Treatment Accreditation Course (OTAC) with options for face to face or online plus monthly clinical case based webinars.
GLAD referrals can be sent via: Email GLAD@svha.org.au
GLAD CNC: Tara Kenny
Addiction Medicine Consultant: Dr Chris Davis
For advice about management of patients with D&A related issues
24/7 telephone advice for NSW health practitioners call DASAS (Drug and Alcohol Specialist Advisory Service) 1800 023 687
For online clinical advice, information and referrals pathways: Sydney Health Pathways or South Eastern Sydney Health Pathways